Jiangsu Jichuan Pharmaceutical

Jiangsu Jichuan Pharmaceutical is a prominent Chinese pharmaceutical group focused on the integration of Traditional Chinese Medicine (TCM), chemical pharmaceuticals, and healthcare products. The company holds a dominant position in the Chinese pediatric and respiratory markets, driven by its core products like Pudilan Xiaoyan Oral Liquid and Xiaoer Chuanzi Qingre Keli. Beyond TCM, Jichuan is actively expanding its footprint in chemical drugs and biologics, evidenced by strategic collaborations for late-stage assets such as long-acting growth hormones. Headquartered in Taizhou, Jiangsu, the company is listed on the Shanghai Stock Exchange and maintains extensive GMP-certified manufacturing capabilities. Jichuan's business model emphasizes a strong domestic sales network and a growing R&D pipeline targeting unmet needs in chronic and acute conditions.